What's in Bayer AG's pipeline?

Bayer AG has 315 drugs in our index: 77 marketed, 0 filed, 68 in Phase 3, 73 in Phase 2, 94 in Phase 1.

Which companies overlap with Bayer AG's portfolio?

Top competitors by shared drug class: Pfizer, GlaxoSmithKline, Merck Sharp & Dohme LLC, Sanofi, Novartis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bayer.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Bayer AG — Portfolio Competitive Intelligence Brief

Bayer AG (BAYRY) pipeline: 77 marketed, 0 filed, 68 Phase 3, 73 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

BAYRY (OTC) 77 marketed 0 filed 68 Phase 3 73 Phase 2 94 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Kerendia	FINERENONE	marketed	Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]	Mineralocorticoid receptor	Metabolic	2021-01-01
Lampit	NIFURTIMOX	marketed	nifurtimox		Infectious Disease	2020-01-01
Nubeqa	darolutamide	marketed		androgen receptor (AR)	Oncology	2019-01-01
Vitrakvi	LAROTRECTINIB	marketed	Kinase Inhibitor [EPC]	High affinity nerve growth factor receptor	Oncology	2018-01-01
Aliqopa	COPANLISIB	marketed	Kinase Inhibitor	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Oncology	2017-01-01
Radium bromatum	RADIUM	marketed			Oncology	2016-01-01
Citomix	INTERFERON	marketed	Lymphocyte Growth Factor [EPC]		Immunology	2015-01-01
Adempas	RIOCIGUAT	marketed	Soluble Guanylate Cyclase Stimulator [EPC]	Guanylate cyclase soluble subunit beta-1	Metabolic	2013-01-01
Xofigo	RADIUM RA 223 DICHLORIDE	marketed	radium Ra 223 dichloride		Oncology	2013-01-01
Stivarga	regorafenib	marketed	Kinase Inhibitor	Bifunctional epoxide hydrolase 2	Oncology	2012-01-01
Gadavist	GADOBUTROL	marketed	Gadolinium-based Contrast Agent [EPC]		Hematology	2011-01-01
Eovist	gadoxetate	marketed	gadoxetate		Infectious Disease	2008-01-01

Therapeutic area mix

Cardiovascular · 26
Oncology · 20
Infectious Disease · 19
Other · 13
Hematology · 9
Diabetes · 7
Dermatology · 7
Metabolic · 6
Immunology · 4
Diagnostic Imaging · 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2027-02-28 — Tussionex Pennkinetic · 7863287 · US
2027-03-15 — Tussionex Pennkinetic · 8790700 · US
2029-03-29 — Tussionex Pennkinetic · 8062667 · US
2029-04-21 — Cipro · 9603796 · Compound · US
2029-04-21 — Cipro · 11369566 · Formulation · US
2029-04-21 — Cipro · 9205048 · Method of Use · US
2029-12-11 — Cipro · 9233068 · Formulation · US
2030-04-27 — Cipro · 8318817 · Method of Use · US
2032-01-03 — Tussionex Pennkinetic · 9066942 · US
2032-01-03 — Tussionex Pennkinetic · 9107921 · US
2035-07-01 — Cipro · 9220796 · Formulation · US
2037-11-12 — Cipro · 11040004 · Method of Use · US
2038-11-27 — Cipro · 11246863 · Formulation · US
2042-05-26 — Lotrimin · 12246006 · Formulation · US

Competitive overlap (companies sharing drug classes)

Pfizer · 13 shared drug classes
GlaxoSmithKline · 9 shared drug classes
Merck Sharp & Dohme LLC · 9 shared drug classes
Sanofi · 9 shared drug classes
Novartis · 9 shared drug classes
Organon and Co · 6 shared drug classes
Hoffmann-La Roche · 6 shared drug classes
Pfizer Inc. · 6 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Bayer AG:

Cite this brief

Drug Landscape (2026). Bayer AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bayer. Accessed 2026-05-13.